Onco-Innovations Cash Flow Statement

Financials in millions CAD. Fiscal year is May - April.

Millions CAD. Fiscal year is May - Apr.

Fiscal Year	FY 2026	FY 2025	FY 2024	FY 2023
Period Ending	Apr '26 Apr 30, 2026	Apr '25 Apr 30, 2025	Apr '24 Apr 30, 2024	Apr '23 Apr 30, 2023
Net Income	-10.78	-7.56	-0.06	-0
Stock-Based Compensation	4.43	1.7	-	-
Other Adjustments	-	2.92	-	-
Change in Receivables	0.04	-0.05	-	-
Changes in Accounts Payable	0.44	0.13	0.06	0
Changes in Other Operating Activities	0.6	-1	-0.01	-
Operating Cash Flow	-5.27	-3.87	-0.01	-0
Operating Cash Flow Growth	-	-	-	-
Other Investing Activities	-	0.1	-	-
Investing Cash Flow	-	0.1	-	-
Long-Term Debt Repaid	-	-0.01	-	-
Net Long-Term Debt Issued (Repaid)	-	-0.01	-	-
Issuance of Common Stock	1.46	0.38	0.08	0.02
Net Common Stock Issued (Repurchased)	1.46	0.38	0.08	0.02
Other Financing Activities	-0.14	-0.12	-	-
Financing Cash Flow	4.93	4.43	0.08	0.02
Net Cash Flow	-0.34	0.66	0.07	0.02
Free Cash Flow	-5.27	-3.87	-0.01	-0
Free Cash Flow Growth	-	-	-	-
FCF Margin	-4772.97%	-5925.34%	-	-
Free Cash Flow Per Share	-0.09	-0.09	-0.00	-233.00
Levered Free Cash Flow	-9.73	-8.44	-0.01	-0
Unlevered Free Cash Flow	-9.73	-5.54	-0.01	-0